Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
In patients with pathological stage I-II-III BC, the phenotypic subgroup influenced the oncologists' decision on the choice of type of adjuvant systemic therapy, as also indicated by international and national guidelines. In our patients, the DFS rate at 24 and 48 months after surgery was 95.4% and 92.8% respectively. The adherence to the AIOM Guidelines in clinical practice was high but having both quality indicators (shared at international and national level) to evaluate the quality of care in BC and standardized threshold levels to evaluate adherence to guidelines is very important today because this type of evaluation will increase in the coming years.
Authors
- Alessio Schirone
- Matteo Valerio (ORCID: https://orcid.org/0000-0001-9156-4941)
- Matteo Verzè
- Lorenzo Gianni (ORCID: https://orcid.org/0000-0002-2618-0180)
- Roberto Bordonaro (ORCID: https://orcid.org/0000-0001-5005-0880)
- Saverio Cinieri (ORCID: https://orcid.org/0000-0002-5555-0814)
- Angela Toss (ORCID: https://orcid.org/0000-0002-1854-6701)
- Patrizia Vici (ORCID: https://orcid.org/0000-0001-7528-9783)
- Elisabetta Cretella (ORCID: https://orcid.org/0000-0001-8491-3058)
- Claudio Zamagni (ORCID: https://orcid.org/0000-0003-0052-2581)
- Francesca Galli (ORCID: https://orcid.org/0000-0003-3091-7306)
- Claudia Bighin
- Catia Angiolini (ORCID: https://orcid.org/0000-0002-7822-7251)
- Stefania Gori (ORCID: https://orcid.org/0000-0001-6320-405X)
- M.F. Alvisi (ORCID: https://orcid.org/0000-0003-0348-1527)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Giancarlo Bisagni (ORCID: https://orcid.org/0000-0003-1042-3771)
- Eliana Rulli (ORCID: https://orcid.org/0000-0003-1058-4137)
- Lucia Borgato
- G. Ferretti (ORCID: https://orcid.org/0000-0002-2271-6427)
- C. Cappelletti
- Irene De Simone (ORCID: https://orcid.org/0000-0002-4806-7904)
- Monica Turazza
- Anna Santoni
- Alessandra Modena
- Fabrizio Nicolis (ORCID: https://orcid.org/0009-0002-3186-1965)
- Piermario Salvini (ORCID: https://orcid.org/0009-0005-8324-4231)
- Anna Cariello (ORCID: https://orcid.org/0000-0002-2579-6661)
- Antonio Dello Russo (ORCID: https://orcid.org/0000-0002-4370-2008)
- Costanza De Rossi (ORCID: https://orcid.org/0000-0002-2020-1032)
Institutions
- University of Modena and Reggio Emilia (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- Agostino Gemelli University Polyclinic (IT)
- Fatih University Medical Faculty Hospital (TR)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Breast Cancer Care (GB)
- Ospedale A. Perrino (IT)
- Ospedale Garibaldi (IT)
- Azienda Unità Sanitaria Locale Della Romagna (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Breast Center (CH)
- Humanitas Gavazzeni (IT)
- Ospedale Infermi di Rimini (IT)
- Azienda Unità Sanitaria Locale Rimini (IT)
- Tumori Foundation (US)
- Ospedale Policlinico San Martino (IT)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Ospedale San Bortolo (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale San Pietro Fatebenefratelli (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fonc.2025.1501667
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87